Document Detail


Lithium toxicity after switch from fosinopril to lisinopril.
MedLine Citation:
PMID:  15729089     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There is a small body of literature on the interactions between lithium and angiotensin-converting enzyme inhibitors (ACEIs), but little data documenting the differences between these agents in their impact on serum lithium levels. We present the case of a 46-year-old male who sustained a five-fold increase in his serum lithium level after switching from fosinopril to lisinopril, with a peak serum lithium level of 3.4 meq/l. There was also an increase in serum creatinine from 1.1 on fosinopril to 1.4 after switching to lisinopril. The patient was hospitalized, and intravenously hydrated with 0.5 normal saline, with a reduction of the serum lithium level to 0.7 meq/l by 72 h after admission. The hospital course was marked by two episodes of bradycardia, but was otherwise uneventful, and the patient was discharged without any neurological sequelae. This case demonstrates that ACEIs may have differential effects on renal function, and the potential for significant alterations in lithium clearance that may not be clinically evident for several weeks. Lithium-treated patients who have a change in ACEI, especially those who are older or have below average renal function, must have diligent monitoring for the first 4-6 weeks after switching to detect potentially serious changes in serum lithium levels.
Authors:
Jonathan M Meyer; Adrian Dollarhide; In-Lin Tuan
Related Documents :
12452369 - Chronic renal failure-induced changes in serum and urine bile acid profiles.
17112859 - Simvastatin down regulates mrna expression of rantes and ccr5 in posttransplant renal r...
781549 - Correlation between red cell and free plasma phenytoin levels in renal disease.
15013329 - The factors affecting blood pressure in pediatric renal transplant recipients.
22012069 - Protective effect of tanshinone iia on rat kidneys during hypothermic preservation.
11423759 - Treatment of severe hypothyroidism reduced serum creatinine levels in two chronic renal...
16536709 - Surgical approach to the coelomic cavity through the axillary and inguinal regions in s...
1694149 - Comparative studies of the healing process after recurrent edematous and hemorrhagic pa...
20534259 - Estimation of the harm to the waiting list as a crucial factor in the selection of pati...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  International clinical psychopharmacology     Volume:  20     ISSN:  0268-1315     ISO Abbreviation:  Int Clin Psychopharmacol     Publication Date:  2005 Mar 
Date Detail:
Created Date:  2005-02-24     Completed Date:  2005-07-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8609061     Medline TA:  Int Clin Psychopharmacol     Country:  England    
Other Details:
Languages:  eng     Pagination:  115-8     Citation Subset:  IM    
Affiliation:
Department of Psychiatry, Veterans Affairs San Diego Healthcare System, University of California, San Diego, CA 92161, USA. jmmeyer@ucsd.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin-Converting Enzyme Inhibitors / adverse effects*,  therapeutic use
Antimanic Agents / adverse effects*,  blood
Bipolar Disorder / drug therapy,  psychology
Bradycardia / chemically induced
Fosinopril / adverse effects*,  therapeutic use
Heart Rate / drug effects
Humans
Lisinopril / adverse effects*,  therapeutic use
Lithium / adverse effects*,  blood
Male
Middle Aged
Psychotic Disorders / drug therapy,  psychology
Chemical
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 0/Antimanic Agents; 7439-93-2/Lithium; 83915-83-7/Lisinopril; 98048-97-6/Fosinopril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of the metabolic effects observed in patients treated with ziprasidone versus olanzapine.
Next Document:  Quetiapine-induced myoclonus.